Sander van Doorn - Concepedia

Author

Sander van Doorn

Utrecht University ORCID

Also Known As

Monika Hollander, S Van Doorn, S van Doorn, S. van Doorn, Sander Doorn, Sander Van Doorn, Sander van Doorn, Y Saito

Publications

912

Citations

H-Index

Concepts

All Affiliations

Utrecht University University Medical Center Utrecht University of Groningen Radboud University Nijmegen Radboud University Medical Center

About

Sander van Doorn is an author at Utrecht University specializing in medicine, atherosclerosis, and cardiovascular disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	233
2	Natural Sciences	1	1	191
3	Public Health	1	1	25
4	Biochemistry	1	1	191
5	Cell Biology	1	1	17

Sander van Doorn

Publications

663

Citations

H-Index

Page 1

	Year	Citations
EGFR Dynamics Change during Activation in Native Membranes as Revealed by NMR Mohammed Kaplan, Siddarth Narasimhan, Cecilia de Heus, Cell Native MembranesProteinlipid InteractionSignal TransductionEgfr Dynamics ChangeBiochemistry	2016	191
Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial Linda P.T. Joosten, Sander van Doorn, Peter M. van de Ven, Circulation	2023	156
Integrated management of atrial fibrillation in primary care: results of the ALL-IN cluster randomized trial Carline J. van den Dries, Sander van Doorn, Frans H. Rutten, European Heart Journal	2020	73
Assessment of SRM, MRM<sup>3</sup>, and DIA for the targeted analysis of phosphorylation dynamics in non‐small cell lung cancer Thierry Schmidlin, Luc Garrigues, Catherine Lane, PROTEOMICS	2016	54
Don't be misled: 3 misconceptions about external validation of clinical prediction models Hannah M la Roi-Teeuw, Florien S van Royen, Anne de Hond, Journal of Clinical Epidemiology	2024	34
Effectiveness of CHA2DS2-VASc based decision support on stroke prevention in atrial fibrillation: A cluster randomised trial in general practice Sander van Doorn, Frans H. Rutten, C.M. O'Flynn, International Journal of Cardiology Cerebrovascular DiseasePharmacotherapyPreventive CardiologyThrombosisStroke	2018	25
Safety of switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulant in frail elderly with atrial fibrillation: rationale and design of the FRAIL-AF randomised controlled trial Linda P.T. Joosten, Sander van Doorn, Arno W. Hoes, BMJ Open	2019	18
Combined EGFR and ROCK Inhibition in Triple-negative Breast Cancer Leads to Cell Death Via Impaired Autophagic Flux Stamatia Rontogianni, Sedef Iskit, Sander van Doorn, Molecular & Cellular Proteomics MitophagyBreast OncologyPathologyCell DeathCancer Biology	2019	17
Adaptive Resistance to EGFR-Targeted Therapy by Calcium Signaling in NSCLC Cells Celine Mulder, Nadine Prust, Sander van Doorn, Molecular Cancer Research	2018	16
Risk of cardiac and non-cardiac adverse events in community-dwelling older patients with atrial fibrillation: a prospective cohort study in the Netherlands Sander van Doorn, Annerien Tavenier, Frans H. Rutten, BMJ Open	2018	16

Page 1